Drug intelligence / Profile preview

VB2-011

Development stage: Preclinical
Modality: Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes

Overview

VB2-011 is an investigational antibody developed as an anti-cancer treatment. It has shown potential in preclinical studies to inhibit tumor growth in various cancers, including lymphoma and melanoma. The drug includes both the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG). It is classified as a protein-based therapy and falls under the category of immunotoxin conjugated to protein. Its precise mechanism of action has not been disclosed in public sources[1][2].

Beyond the preview

Go deeper on VB2-011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VB2-011.

Explore the full profile